Anna Martling

Anna Martling

Professor/Överläkare
E-postadress: anna.martling@ki.se
Telefon: +46852482725
Besöksadress: Elite Hotell, plan 2, Eugeniavägen 6, 17176 Stockholm
Postadress: K1 Molekylär medicin och kirurgi, K1 MMK Kolorektalkirurgi, 171 76 Stockholm
Del av:

Om mig

  • Anna Martling är professor i kirurgi vid Karolinska Institutet, Stockholm, Sverige. Hon försvarade sin avhandling om ändtarmscancer 2003, blev certifierad kirurg 2004, docent 2009. 2014 blev Martling professor i kirurgi. Mellan 2019-2023 var Anna Martling dekan vid Karolinska Institutet. Mellan åren 2020-2024 innehade hon rollen att koordinera och driva implementeringen av precisionsmedicin in i hälso- och sjukvården inom Region Stockholm. Under 2024 verkade professor Martling som Scientific Director Life Science Karolinska Institutet. Stockholm.

    Sedan 2008 leder hon forskargruppen och ansvarar för forskningsområdet kolorektalkirurgi med särskilt fokus på kliniska-, translationella och epidemiologiska studier av kolorektal cancer. Ett särskilt intresse för Martlings forskargrupp har varit prediktiva och prognostiska biomarkörer, acetylsalicylsyra, strålbehandling, tidpunkt för operation och utveckling av nya kirurgiska tekniker. Anna Martling har lyckats integrera forskargruppens arbete fullt ut i kliniken och har skapat en unik kreativ och akademisk kultur som stödjer högkvalitativ klinisk forskning. Hennes forskning har fått ett flertal priser. 2013 fick Anna Martling Svensk Kirurgisk förenings Stora Forskningspris. 2021 fick hon priset Årets cancerforskare av Cancerfonden.

    Hon anses vara en världsledande expert inom sitt område och är en frekvent föreläsare i Sverige och utomlands. Professor Martling är hedersledamot vid Royal College of Surgeon of England (FRCS), American Colleges of Surgeons (FACS) och American Society of Colorectal Surgeons (FASCRS). Professor Martling är ordförande i Swedish Colorectal Cancer Study Group, som är ett nationellt forskningsnätverk för kolorektal cancer i Sverige. Mellan 2015-2018 var hon ordförande i European Society of ColoProctologys (ESCP:s) programkommitté och ansvarig för det vetenskapliga programmet för ESCP:s årliga möte. Sedan 2020 är professor Martling koordinerande ordförande för arbetsgruppen för implementering av precisionsmedicin i vården i Region Stockholm. Anna Martlings forskning finansieras av Vetenskapsrådet, Cancerfonden, Radiumhemmets forskningsfonder, KI och Region Stockholm. 2014 mottog hon Vetenskapsrådets dittills största bidrag för klinisk behandlingsforskning på 25 miljoner kronor.

    Angelägna frågor

    Vi på Karolinska Institutet (KI) måste gemensamt skapa en stimulerande och forskningsfaciliterande miljö som möjliggör en världsledande grundvetenskaplig-, translationell-, och klinisk forskning och som tillsammans skapar värde genom att bidra med kunskap om livet och som förbättrar människors hälsa. En viktig komponent i detta är införandet av det som har kommit att kallas precisionsmedicin. Genom att driva detta projekt i samverkan mellan KI, SciLifeLab, Karolinska Universitetssjukhuset och Region Stockholm hoppas vi kunna uppnå att viktiga medicinska framsteg, nya rön och teknologier kan implementeras i vården och skapa mer precisa, individualiserade diagnostiker och terapier i absolut framkant. En annan viktig komponent för att uppnå detta är att vi gemensamt skapar förutsättningar för lagring, bearbetning, integrering och analys av stora mängder komplexa data, vilket bidrar till utvecklandet av precisionsmedicin men även möjliggör secondary use av hälsodata för forskning.

    KI står samtidigt inför nya utmaningar men också betydande möjligheter i och med de stora förändringarna av sjukvårdsstrukturen inom Region Stockholm. Det är då av yttersta vikt att det medicinska universitetet KI är aktivt och delaktigt i de förändringar som vi står inför och tillvaratar tillfället att bygga en excellent forskning- och utbildningsmiljö för framtiden där forskning och utbildning är integrerade och naturliga delar av vårt sjukvårdssystem på alla nivåer, oavsett driftsform och vårdgivare.

    Akademiska priser och utmärkelser
    2023 Honorary Fellow of European Society of Coloproctology (FESCP)

    2023 Honorary Fellow of American College of Surgeons (FACS)

    2022 Honorary Fellow of Royal College of Surgeons of England (FRCS)

    2021 Årets Cancerforskare, Cancerfonden

    2020 Honorary Fellowship of American Society of Colon and Rectal Surgeons (FASCRC)

    2019 Tarmcancerpriset, ILCO

    2019 Med dr Axel Hirsch Pris, Karolinska Institutet 2018 Hilda och Alfred Erikssons pris, Kungliga Vetenskaps Akademin

    2017 Marc-Claude Marti Lecture, Villars, Schweiz

    2016 Årets Lennanderföreläsare, Svenska Läkaresällskapet

    2015 The Edward Wilson Lecture, Sydney, Australia

    2013 Svensk Kirurgisk Förenings Stora Forskarpris

Forskningsbeskrivning

  • Ansvarig huvudprövare (PI) för forskningsstudierna ALASCCA och CITCCA

Utvalda publikationer

Artiklar

Alla övriga publikationer

Utvalda forskningsbidrag

  • Swedish Research Council
    1 January 2023 - 31 December 2026
    The rapid development of technologies for molecular profiling paves the way for precision medicine approaches to match patients with effective treatment. Through the development of a coordinating support unit, we aim to provide access to SciLifeLab’s technology platforms to support academic and industry-initiated clinical trials. We will establish customized diagnostic packages jointly with clinical trials units across the country to strengthen our attractiveness as a clinical trial site and to ensure early access of patients to both innovative technologies and emerging treatments.Our goal is to identify mature technologies to be evaluated in observational studies and adopted in interventional biomarker-driven clinical trials. To build this capacity, connecting SciLifeLab national infrastructure to clinical practice, key developments supporting cross-platform data, sample and analysis flows with timelines and quality complying with the needs of clinical trials are needed. Our unit will unite services from current and emerging sequencing technologies, to proteome, metabolome, spatial biology techniques, and drug efficacy testing. Our competitive edge is the repertoire of technologies at SciLifeLab, which once combined provide a unique opportunity for clinical trials. With the ‘service packages’ we aim to make Sweden competitive as a trial site, catalyze academy-industry ecosystems and provide opportunities for early access to the latest diagnostic technologies and treatments.
  • Swedish Research Council
    1 January 2014 - 31 December 2019

Forskningsbidrag

  • Swedish Research Council
    1 January 2020 - 31 December 2020
  • Improved patient-specific investigation, treatment and rehabilitation of patients with rectal cancer
    Swedish Cancer Society
    1 January 2018
    Thick and rectal cancer annually affects about 6,000 people. The treatment is essentially surgical. In recent years, treatment has improved, which has led to increased survival in the disease, but still nearly half of the patients suffer from difficult-to-treat relapses. In spite of a localized tumor, 20-40% of patients will develop remote proliferation at high risk of death. In spreading disease there are new treatments that prolong survival, but only in a small proportion of patients leads to cure. Improved add-on treatments - in order to reduce the risk of relapse - would therefore be of greatest value. We are towards the final phase of a randomized multicentre study that studies the value of different radiation treatment regimens where the results show that a newly introduced regimen can reduce the risk of side effects by about 40% while maintaining good oncological results. Furthermore, sexual function and hormones are studied after radiation therapy, which has been sparingly studied previously. Treatment with acetylsalicylic acid (ASA) has shown to reduce the incidence of polyps, reduce the risk of colon and rectal cancer and also reduce the risk of developing daughter tumors. We have now initiated the first biomarker-based study of treatment with ASA in patients with colorectal cancer. Our clinical, patient-related research on various aspects of diagnosis, treatment and prognosis in rectal cancer has resulted in altered treatment strategies and reduced local recurrence rates and improved survival. The research program aims at a more patient-specific cancer incident throughout the care chain from diagnostics to rehabilitation, thereby increasing the chances of cure and a reduced suffering of side effects. Furthermore, we hope that further improved supplementary treatments will reduce the risk of relapse. Our studies are all well applicable in clinical practice and will immediately benefit the patients.
  • Improved patient-specific investigation, treatment and rehabilitation of patients with rectal cancer
    Swedish Cancer Society
    1 January 2017
    Thick and rectal cancer annually affects about 6,000 people. The treatment is essentially surgical. In recent years, treatment has improved, which has led to increased survival in the disease, but still nearly half of the patients suffer from difficult-to-treat relapses. In spite of a localized tumor, 20-40% of patients will develop remote proliferation at high risk of death. In spreading disease there are new treatments that prolong survival, but only in a small proportion of patients leads to cure. Improved add-on treatments - in order to reduce the risk of relapse - would therefore be of greatest value. We are towards the final phase of a randomized multicentre study that studies the value of different radiation treatment regimens where the results show that a newly introduced regimen can reduce the risk of side effects by about 40% while maintaining good oncological results. Furthermore, sexual function and hormones are studied after radiation therapy, which has been sparingly studied previously. Treatment with acetylsalicylic acid (ASA) has shown to reduce the incidence of polyps, reduce the risk of colon and rectal cancer and also reduce the risk of developing daughter tumors. We have now initiated the first biomarker-based study of treatment with ASA in patients with colorectal cancer. Our clinical, patient-related research on various aspects of diagnosis, treatment and prognosis in rectal cancer has resulted in altered treatment strategies and reduced local recurrence rates and improved survival. The research program aims at a more patient-specific cancer incident throughout the care chain from diagnostics to rehabilitation, thereby increasing the chances of cure and a reduced suffering of side effects. Furthermore, we hope that further improved supplementary treatments will reduce the risk of relapse. Our studies are all well applicable in clinical practice and will immediately benefit the patients.
  • Sexual function, well-being and hormone levels in women and men with rectal cancer: the importance of early intervention and sexual rehabilitation
    Swedish Cancer Society
    1 January 2016
    Intestinal cancer is the seventh most common form of cancer and is mainly treated with surgery, sometimes in combination with radiation therapy. However, the treatment may cause side effects. Sexual dysfunction is well described in men, but less in women. The cause may be the surgical trauma, lack of intestinal function, urinary incontinence, stoma and bodily changes. In the radiation treatment, ovaries and testicles are exposed to radiation, which can lead to premature menopause, infertility, fragile mucous membranes and intercourse pain, and possibly a hormone deficiency. In men, decreased testosterone levels are seen, in women this has not previously been studied. We intend to study how radiation therapy and pelvic surgery in women and men with rectal cancer affect hormone levels, sexual function and well-being. In men, the influence on sperm production will also be studied, which has also been sparingly studied previously. Based on the results of the previous studies within the project, we have initiated a new study that studies the value of early intervention with the addition of PDE-5 inhibitors in low dose and testosterone substitution on sexual function after treatment of rectal cancer which has not previously been studied. In recent decades, treatment and prognosis in rectal cancer has improved significantly and more and more people survive the disease. It is thus becoming increasingly important to study the quality of life after the treatment has been completed. The objectives of the project are to increase knowledge of sexual function, quality of life and hormone levels after radiotherapy and surgery in women and men with rectal cancer and to improve the care of this large patient group regarding psychosexual prevention, information, rehabilitation and intervention.
  • Sexual function, well-being and hormone levels in women and men with rectal cancer: the importance of early intervention and sexual rehabilitation
    Swedish Cancer Society
    1 January 2015
    Intestinal cancer is the seventh most common form of cancer and is mainly treated with surgery, sometimes in combination with radiation therapy. However, the treatment may cause side effects. Sexual dysfunction is well described in men, but less in women. The cause may be the surgical trauma, lack of intestinal function, urinary incontinence, stoma and bodily changes. In the radiation treatment, ovaries and testicles are exposed to radiation, which can lead to premature menopause, infertility, fragile mucous membranes and intercourse pain, and possibly a hormone deficiency. In men, decreased testosterone levels are seen, in women this has not previously been studied. We intend to study how radiation therapy and pelvic surgery in women and men with rectal cancer affect hormone levels, sexual function and well-being. In men, the influence on sperm production will also be studied, which has also been sparingly studied previously. Based on the results of the previous studies within the project, we have initiated a new study that studies the value of early intervention with the addition of PDE-5 inhibitors in low dose and testosterone substitution on sexual function after treatment of rectal cancer which has not previously been studied. In recent decades, treatment and prognosis in rectal cancer has improved significantly and more and more people survive the disease. It is thus becoming increasingly important to study the quality of life after the treatment has been completed. The objectives of the project are to increase knowledge of sexual function, quality of life and hormone levels after radiotherapy and surgery in women and men with rectal cancer and to improve the care of this large patient group regarding psychosexual prevention, information, rehabilitation and intervention.
  • Sexual function, well-being and hormone levels in women and men with rectal cancer: the importance of early intervention and sexual rehabilitation
    Swedish Cancer Society
    1 January 2014
    Intestinal cancer is the seventh most common form of cancer and is mainly treated with surgery, sometimes in combination with radiation therapy. However, the treatment may cause side effects. Sexual dysfunction is well described in men, but less in women. The cause may be the surgical trauma, lack of intestinal function, urinary incontinence, stoma and bodily changes. In the radiation treatment, ovaries and testicles are exposed to radiation, which can lead to premature menopause, infertility, fragile mucous membranes and intercourse pain, and possibly a hormone deficiency. In men, decreased testosterone levels are seen, in women this has not previously been studied. We intend to study how radiation therapy and pelvic surgery in women and men with rectal cancer affect hormone levels, sexual function and well-being. In men, the influence on sperm production will also be studied, which has also been sparingly studied previously. Based on the results of the previous studies within the project, we have initiated a new study that studies the value of early intervention with the addition of PDE-5 inhibitors in low dose and testosterone substitution on sexual function after treatment of rectal cancer which has not previously been studied. In recent decades, treatment and prognosis in rectal cancer has improved significantly and more and more people survive the disease. It is thus becoming increasingly important to study the quality of life after the treatment has been completed. The objectives of the project are to increase knowledge of sexual function, quality of life and hormone levels after radiotherapy and surgery in women and men with rectal cancer and to improve the care of this large patient group regarding psychosexual prevention, information, rehabilitation and intervention.
  • Swedish Research Council
    1 January 2014 - 31 December 2016
  • Swedish Research Council
    1 January 2011 - 31 December 2012

Anställningar

  • Professor/Överläkare, Molekylär medicin och kirurgi, Karolinska Institutet, 2014-

Examina och utbildning

  • Docent, Kirurgi, Karolinska Institutet, 2009
  • MEDICINE DOKTORSEXAMEN, INST F KIRURGISK VETENSKAP (K3), Karolinska Institutet, 2003
  • Läkarexamen, Karolinska Institutet, 1994

Uppdrag

  • Forskargruppsledare, CITCCA - CIrculating Tumour DNA in Colorectal CAncer, Karolinska Institutet, 2020-
  • Forskargruppsledare, EROS - EaRly interventiOn and Sexual rehabilitation, Karolinska Institutet, 2018-
  • Forskargruppsledare, ALASCCA-trial
  • Adjuvant Low dose ASpirin in patients with Colorectal CAncer, Karolinska Institutet, 2016-
  • Forskargruppsledare, Stockholm III Trial, Karolinska Institutet, 2007-2013

Priser och utmärkelser

  • Honorary Fellow of American College of Surgeons (FACS), American College of Surgeons, 2023
  • Honorary Fellow of European Society of Coloproctology (FESCP), European Society of Coloproctology, 2023
  • Honorary Fellow of Royal College of Surgeons of England (FRCS), Royal College of Surgeons of England, 2022
  • Member, BJS Award Committee, 2022
  • Årets Cancerforskare, Cancerfonden, Swedish Cancer Society, 2021
  • Honorary Fellowship, American Society of Colon and Rectal Surgeons, 2020
  • Member, International Surgical Group (ISG), 2020
  • Med dr Axel Hirsch Pris, Karolinska Institutet, Karolinska Institutet, 2019
  • Tarmcancerpriset, ILCO, Tarm- uro- och stomiförbundet, ILCO, Tarm- uro- och stomiförbundet, 2019
  • Hilda och Alfred Erikssons pris, Kungliga Vetenskapsakademin, Royal Swedish Academy of Sciences, 2018
  • Marc-Claude Marti Lecture, Villars, Switzerland, 2017
  • Årets Lennanderföreläsare, Svenska Läkaresällskapet, Swedish Society of Medicine, 2016
  • Six best papers award, ESCP meeting, 2016
  • Six best papers award, ESCP meeting, 2015
  • The Edward Wilson Lecture, Sydney, Australia, 2015
  • Svensk Kirurgisk Förenings Stora Forskarpris, Swedish Surgical Society, 2013
  • Six best papers award, ESCP meeting, 2012
  • Young Investigator Award, 6 years of salary stipend for postdoctoral researchers in Sweden working on cancer research, Cancerfonden, 2008
  • Six best papers award, ESCP meeting, 2008
  • Young Promising Researcher, Karolinska Institutet, 2003

Uppdrag i kommitté

  • Medlem, Styrgrupp, Swedish Quantum Life Science Center, 2023-
  • Medlem, Steering committee, Genomic Medicine Sweden (GMS), 2023-
  • Medlem, Board of Trustees, European Society of Coloproctology (ESCP), 2021-
  • Medlem, Styrgrupp, Clinicum, Karolinska Institutet, 2021-
  • Medlem, Styrelse, Cancerfonden, 2020-2023
  • Ordförande, Task-force Precision Medicine, Karolinska Institutet, 2020-
  • Medlem, Board, Forska Sverige, 2020-
  • Medlem, Board of Directors, Karolinska Cancer Comprehensive Center (KCCC), 2020-
  • Ordförande, Stiftelsen Konung Gustaf V:s Jubileumsfond, 2019-2024
  • Medlem, Board, KI/Region Stockholm, 2019-
  • Medlem, Board, Bactiguard (Sweden), 2019-
  • Medlem, Board, S:t Eriks Ögonsjukhus, 2019-
  • Medlem, Faculty Board, Karolinska Institutet, 2019-
  • Medlem, Board of Directors, Centrum for Innovative Medicine (CIMED), 2018-
  • Medlem, Board of Research, Karolinska Institutet, 2015-2018
  • Ordförande, Program/Scientific Committee, European Society of Coloproctology (ESCP), 2015-2018
  • Ordförande, Swedish Colorectal Cancer Study Group, 2015-
  • Medlem, Scientific Committee and Research Council, Swedish Cancer Society, 2012-2017
  • Medlem, Scientific committee, Swedish Cancer Society, 2012-2018
  • Ordförande, Bengt Ihre Research Fellowship, 2012-2016
  • Medlem, United European Gastroenterology Federation Scientific Committee, 2010-2012
  • Ordförande, Stockholm Colorectal Cancer Study Group, 2008-
  • Medlem, Steering Committee, Swedish Colorectal Cancer Registry, 2008-2019
  • Annat, Advisor, ad hoc committee for development of National Centers of Excellence for the Treatment of Rectal Cancer, American Society of Colon and Rectal Surgeons, 2008-2008
  • Medlem, Swedish Colorectal Surgery Society, 2004-2006

Redaktör för vetenskaplig tidskrift

  • British Journal of Surgery, Medlem i redaktionskommittén, 2016
  • European Journal of Surgical Oncology, Biträdande redaktör, 2014-2017
  • Colorectal Disease, Biträdande redaktör, 2014-2019

Nyheter från KI

Kalenderhändelser från KI